IBCT2

Completed

Incretin Based Therapy for Poorly Controlled Type 2 Diabetic Patients

Clinical and Genetic Variations Study of Incretin Based Therapy for Poorly Controlled Type 2 Diabetic Patients

Lead sponsor

Chang Gung Memorial Hospital

Asset

GLP-1 / incretin class catch-all

Listed sites

Recruiting sites

Actual enrollment

Study population

Type 2 diabetes

Eligibility highlights

•HbA1c 8-12%

Primary endpoint

•Mean amplitude of glycaemic excursions (MAGE)

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT02026024

Org study ID102-3596B

Timeline

Milestones

Study first posted2014-01-01estimated

Last update posted2016-02-02estimated

Study start2013-10 (month precision)

Primary completion2015-12actual (month precision)

Study completion2015-12actual (month precision)

Assets

Investigational agents

GLP-1 / incretin class catch-all

Who this study enrolls

Type 2 diabetes

Who can enroll

Minimum age20 Years

Maximum age80 Years

SexAll

Healthy volunteersNot accepted

Sampling methodProbability sample

Study population text

Poorly Controlled Type 2 Diabetic Patients

Inclusion criteria

•i) Age > 20 years old ii)DM (diabetes mellitus) diagnosed > 2 years iii)HbA1c level of 8% to 12% iv) Receiving incretin based therapy at least one month (including either GLP-1 agonist or DPP(dipeptidyl peptidase)-IV inhibitor

Exclusion criteria

•Type 1 Diabetes Mellitus

Endpoints (1)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Glycemic / diabetes

1 endpoint

Primary/protocol endpoint

mean amplitude of glycaemic excursions (MAGE)

Time frame:3 months

descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 6, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 6, 2026 snapshot.